Clinical performance of hydrophilic, titanium‐zirconium dental implants in patients with well‐controlled and poorly controlled type 2 diabetes: One‐year results of a dual‐center cohort study. Issue 5 (3rd January 2022)

• Record Type: Journal Article
• Authors: Latimer, Jessica M.; Roll, Katherine L.; Daubert, Diane M.; Zhang, Hai; Shalev, Tamir; Wolff, Larry F.; Kotsakis, Georgios A.
• Is Part Of: Journal of periodontology. Volume 93:Issue 5(2022)
• Page Start: 745
• Page End: 757
• Publication Date: 2022-01-03
• Subjects: dental implants -- diabetes -- hyperglycemia -- Ti‐Zr alloy; Periodontics -- Periodicals; 617.632
• DOI: 10.1002/JPER.21-0015
• Languages: English
• ISSNs: 0022-3492

Abstract

Abstract: Background: This study assessed the clinical performance of hydrophilic dental implants in a patient cohort with type 2 diabetes mellitus (T2DM). Methods: Subjects with T2DM of ≥2‐years duration were allocated to either the well‐controlled (WC; HbA1c ≤ 7.0%, ) or poorly‐controlled (PC; 7.5 < HbA1c < 10%) groups in a dual‐center, prospective cohort study. Each subject received a single, titanium‐zirconium (Ti‐Zr) dental implant with a chemically‐modified, hydrophilic (modSLA) surface in a posterior mandibular site. Postoperatively, subjects were followed at 1, 2, 4, 8, and 12‐week intervals. Post‐loading, subjects were followed at 3, 6, and 12‐months. Clinical and radiographic parameters of implant success, and dental patient‐reported outcomes were collected. Results: Twenty‐one dental patients ( N WC = 11; N PC = 10; mean age: 66.8 ± 7.5 years) were enrolled and the 1‐year implant success rate was 100%. Peri‐implant bone levels were stable with 0.15 ± 0.06 mm mean marginal loss at 1 year without significant inter‐group differences ( P = 0.79). Postoperative pain was minimal at 1‐week, and OHIP‐5 scores decreased significantly over time as compared with preoperative levels ( P < 0.001) suggesting significant improvement in patient‐perceived oral health following implant therapy. Conclusions: Elevated HbA1c levels > 7.5% did not compromise 1‐year success rates, or oral health‐related quality of life in PC patients receiving modSLA, Ti‐Zr implants. Given that implant placement up to 10% HbA1c significantly enhanced oral health‐related quality of life without complications or morbidity, the safety and efficacy of implants to improve oral function in T2DM is supported, even without ideal glycemic control.